Literature DB >> 1831360

Streptozotocin-induced suppression of FAD-linked glycerophosphate dehydrogenase in pancreatic islets of adult rats.

J Rasschaert1, W J Malaisse.   

Abstract

Injection of streptozotocin (30-40 mg/kg body weight) to adult rats caused within 4-6 days a sizeable decrease in the activity of FAD-linked glycerophosphate dehydrogenase in pancreatic islets, with little change in either glutamate dehydrogenase or 2-oxoglutarate dehydrogenase activity. The severity of the enzymatic defect was related to that of the diabetic state, although a decreased enzymic activity was also observed in islets from virtually normoglycemic animals examined 2-3 weeks after streptozotocin injection. The administration of nicotinamide prior to that of streptozotocin prevented the change in enzymic activity. It is proposed that the enzymatic defect, rather than being attributable to a genomic effect of streptozotocin, may reflect the preferential impairment of a subpopulation of pancreatic B-cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1831360

Source DB:  PubMed          Journal:  Biochem Int        ISSN: 0158-5231


  4 in total

1.  Impaired FAD-glycerophosphate dehydrogenase activity in islet and liver homogenates of fa/fa rats.

Authors:  J Rasschaert; F Malaisse-Lagae; A Sener; V Leclercq-Meyer; L Herberg; W J Malaisse
Journal:  Mol Cell Biochem       Date:  1994-06-29       Impact factor: 3.396

2.  Effect of streptozotocin and nicotinamide upon FAD-glycerophosphate dehydrogenase activity and insulin release in purified pancreatic B-cells.

Authors:  J Rasschaert; Z Ling; W J Malaisse
Journal:  Mol Cell Biochem       Date:  1993-03-24       Impact factor: 3.396

Review 3.  Is type 2 diabetes due to a deficiency of FAD-linked glycerophosphate dehydrogenase in pancreatic islets?

Authors:  W J Malaisse
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

4.  Streptozotocin-induced FAD-glycerophosphate dehydrogenase suppression in pancreatic islets. Relationship with the severity and duration of hyperglycaemia and resistance to insulin or riboflavin treatment.

Authors:  J Rasschaert; W J Malaisse
Journal:  Acta Diabetol       Date:  1993       Impact factor: 4.280

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.